Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
UDP-GalNAc + Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside
UDP + Gal-beta-(1,4)-GalNAc-beta(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside
26.2% of the activity with GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside
-
-
?
UDP-GalNAc + Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-[Fuc-alpha-(1,6)]-GlcNAc-2-pyridylaminoside
UDP + GalNAc-beta(1,4)-Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-[Fuc-alpha-(1,6)]-GlcNAc-2-pyridylaminoside
26.7% of the activity with GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside
-
-
?
UDP-GalNAc + GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside
UDP + GalNAc-beta(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside
16.2% of the activity with GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside
-
-
?
UDP-GalNAc + GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-[Fuc-alpha-(1,6)]-GlcNAc-2-pyridylaminoside
UDP + GalNAc-beta(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-[Fuc-alpha-(1,6)]-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside
3.4% of the activity with GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside
-
-
?
UDP-GalNAc + GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside
UDP + GalNAc-beta(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside
-
-
-
?
UDP-GalNAc + GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-[Fuc-alpha-(1,6)]-GlcNAc-2-pyridylaminoside
UDP + GalNAc-beta(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside
76.8% of the activity with GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside
-
-
?
UDP-GalNAc + GlcNAc-beta-(1,3)-GalNAc-alpha-p-nitrophenyl
UDP + GalNAc-beta-(1,4)-GlcNAc-beta-(1,3)-GalNAc-alpha-p-nitrophenyl
20.0% of the activity with GlcNAcbeta-O-benzyl
-
-
?
UDP-GalNAc + GlcNAc-beta-(1,6)-GalNAc-alpha-p-nitrophenyl
UDP + GalNAc-beta-(1,4)-GlcNAc-beta-(1,6)-GalNAc-alpha-p-nitrophenyl
190.7% of the activity with GlcNAcbeta-O-benzyl
-
-
?
UDP-GalNAc + GlcNAc-beta-(1,6)[Gal-beta-(1,3)]GalNAc-alpha-p-nitrophenyl
UDP + GalNAc-beta-(1,4)-GlcNAc-beta-(1,6)[Gal-beta-(1,3)]GalNAc-alpha-p-nitrophenyl
15.2% of the activity with GlcNAcbeta-O-benzyl
-
-
?
UDP-GalNAc + GlcNAcbeta-O-benzyl
UDP + GalNAc-beta-(1,4)-GlcNAcbeta-O-benzyl
-
-
-
?
UDP-GalNAc + Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside
UDP + Gal-beta-(1,4)-GalNAc-beta(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside
45% of the activity with GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside
-
-
?
UDP-GalNAc + Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-[Fuc-alpha-(1,6)]-GlcNAc-2-pyridylaminoside
UDP + GalNAc-beta(1,4)-Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-[Fuc-alpha-(1,6)]-GlcNAc-2-pyridylaminoside
51.7% of the activity with GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside
-
-
?
UDP-GalNAc + GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside
UDP + GalNAc-beta(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside
21.6% of the activity with GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside
-
-
?
UDP-GalNAc + GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-[Fuc-alpha-(1,6)]-GlcNAc-2-pyridylaminoside
UDP + GalNAc-beta(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-[Fuc-alpha-(1,6)]-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside
5% of the activity with GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside
-
-
?
UDP-GalNAc + GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside
UDP + GalNAc-beta(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside
-
-
-
?
UDP-GalNAc + GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-[Fuc-alpha-(1,6)]-GlcNAc-2-pyridylaminoside
UDP + GalNAc-beta(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside
87.1% of the activity with GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside
-
-
?
UDP-GalNAc + GlcNAc-beta-(1,3)-GalNAc-alpha-p-nitrophenyl
UDP + GalNAc-beta-(1,4)-GlcNAc-beta-(1,3)-GalNAc-alpha-p-nitrophenyl
-
-
-
-
?
UDP-GalNAc + GlcNAcbeta-O-benzyl
UDP + GalNAc-beta-(1,4)-GlcNAcbeta-O-benzyl
-
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + N-acetyl-beta-D-glucosamine
UDP + N-acetyl-beta-D-galactosaminyl-(1->4)-N-acetyl-beta-D-glucosamine
enzyme B4GALNT3 transfers N-acetylgalactosamine (GalNAc) to the non-reducing N-acetylglucosamine (GlcNAc) to form GalNAcbeta1-4GlcNAc (LacdiNAc) in an in vitro enzymatic assay
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + N-acetyl-beta-D-glucosaminyl group
UDP + N-acetyl-beta-D-galactosaminyl-(1->4)-N-acetyl-beta-D-glucosaminyl group
-
-
-
?
additional information
?
-
additional information
?
-
the enzyme mediates the protein-specific addition of beta1,4-linked GalNAc to core 2 O-linked structures both in vivo and in vitro
-
-
?
additional information
?
-
the enzyme could transfer GalNAc residues, producing N,N'-diacetylgalactosediamine structures at least in N-glycans and probably in both N- and O-glycans
-
-
?
additional information
?
-
-
the enzyme could transfer GalNAc residues, producing N,N'-diacetylgalactosediamine structures at least in N-glycans and probably in both N- and O-glycans
-
-
?
additional information
?
-
the most efficient acceptor substrate in the N-glycans examined is a non-fucosylated bi-antennary one. The enzyme shows no activity towards chondroitin-related acceptors containing GlcUA as their non-reducing termini
-
-
?
additional information
?
-
-
the most efficient acceptor substrate in the N-glycans examined is a non-fucosylated bi-antennary one. The enzyme shows no activity towards chondroitin-related acceptors containing GlcUA as their non-reducing termini
-
-
?
additional information
?
-
enzyme B4GALNT3 primarily modifies N-glycans of epithelial growth factor receptor, EGFR, in LacdiNAc by Wisteria floribunda agglutinin pull down assays
-
-
?
additional information
?
-
-
enzyme B4GALNT3 primarily modifies N-glycans of epithelial growth factor receptor, EGFR, in LacdiNAc by Wisteria floribunda agglutinin pull down assays
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Gotoh, M.; Sato, T.; Kiyohara, K.; Kameyama, A.; Kikuchi, N.; Kwon, Y.D.; Ishizuka, Y.; Iwai, T.; Nakanishi, H.; Narimatsu, H.
Molecular cloning and characterization of beta1,4-N-acetylgalactosaminyltransferases IV synthesizing N,N'-diacetyllactosediamine
FEBS Lett.
562
134-140
2004
Homo sapiens (Q76KP1), Homo sapiens
brenda
Ikehara, Y.; Sato, T.; Nakamura, S.; Gotoh, M.; Ikehara, S.K.; Kiyohara, K.; Aoki, C.; Iwai, T.; Nakanishi, H.; Hirabayashi, J.; Tatematsu, M.; Narimatsu, H.
Apical Golgi localization of N,N'-diacetyllactosediamine synthase, beta4GalNAc-T3, is responsible for LacdiNAc expression on gastric mucosa
Glycobiology
16
777-785
2006
Homo sapiens
brenda
Sato, T.; Gotoh, M.; Kiyohara, K.; Kameyama, A.; Kubota, T.; Kikuchi, N.; Ishizuka, Y.; Iwasaki, H.; Togayachi, A.; Kudo, T.; Ohkura, T.; Nakanishi, H.; Narimatsu, H.
Molecular cloning and characterization of a novel human beta1,4-N-acetylgalactosaminyltransferase, beta4GalNAc-T3, responsible for the synthesis of N,N'-diacetyllactosediamine, GalNAc beta1-4GlcNAc
J. Biol. Chem.
278
47534-47544
2003
Homo sapiens (Q6L9W6), Homo sapiens
brenda
Malagolini, N.; Santini, D.; Chiricolo, M.; DallOlio, F.
Biosynthesis and expression of the Sda and sialyl Lewis x antigens in normal and cancer colon
Glycobiology
17
688-697
2007
Homo sapiens
brenda
Huang, J.; Liang, J.T.; Huang, H.C.; Shen, T.L.; Chen, H.Y.; Lin, N.Y.; Che, M.I.; Lin, W.C.; Huang, M.C.
Beta1,4-N-acetylgalactosaminyltransferase III enhances malignant phenotypes of colon cancer cells
Mol. Cancer Res.
5
543-552
2007
Homo sapiens
brenda
Fiete, D.; Beranek, M.; Baenziger, J.U.
Peptide-specific transfer of N-acetylgalactosamine to O-linked glycans by the glycosyltransferases beta1,4-N-acetylgalactosaminyl transferase 3 (beta4GalNAc-T3) and beta4GalNAc-T4
J. Biol. Chem.
287
29204-29212
2012
Homo sapiens (Q76KP1)
brenda
Che, M.I.; Huang, J.; Hung, J.S.; Lin, Y.C.; Huang, M.J.; Lai, H.S.; Hsu, W.M.; Liang, J.T.; Huang, M.C.
beta1,4-N-acetylgalactosaminyltransferase III modulates cancer stemness through EGFR signaling pathway in colon cancer cells
Oncotarget
5
3673-3684
2014
Homo sapiens (Q6L9W6), Homo sapiens
brenda